Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.

[1]  L. Dogliotti,et al.  Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases , 1998, Tumori.

[2]  J. Moul,et al.  Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients , 1997, Cancer.

[3]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[4]  S. Fosså,et al.  Assessment of hormone refractory prostate cancer. , 1997, Urology.

[5]  M. van Glabbeke,et al.  Phase II studies on prostate cancer. , 1997, Urology.

[6]  U. Stenman,et al.  Prostate-specific antigen, clinical use and staging: an overview. , 1997, British journal of urology.

[7]  R. Dreicer.  Metastatic prostate cancer: assessment of response to systemic therapy. , 1997, Seminars in urologic oncology.

[8]  T. M. Chu,et al.  Prostate-specific antigen and early detection of prostate cancer. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[9]  R. Rubinov,et al.  Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. , 1997, European urology.

[10]  F. Koga,et al.  [Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma]. , 1996, Hinyokika kiyo. Acta urologica Japonica.

[11]  W. Catalona.  Clinical utility of measurement free and total prostate‐specific antigen (PSA): A review , 1996, The Prostate. Supplement.

[12]  M. Egorin,et al.  Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. , 1995, Journal of Clinical Oncology.

[13]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[14]  M. Manyak,et al.  Practice trends in the diagnosis and management of prostate cancer in the United States. , 1995, The Journal of urology.

[15]  D. Osoba,et al.  Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Ansong.  Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. , 1994, Urology.

[17]  H. Lilja,et al.  Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. , 1993, Urology.

[18]  U. Stenman,et al.  Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.

[19]  S. Rosso,et al.  Cancer Incidence in Turin: The Effect of Migration , 1993, Tumori.

[20]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[21]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Miller,et al.  The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.

[23]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[24]  J. Oesterling,et al.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.

[25]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[26]  N. Geller,et al.  Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Whitmore.  The natural history of prostatic cancer , 1973, Progress in clinical and biological research.

[28]  Elisa T. Lee,et al.  A computer program for comparing K samples with right-censored data. , 1972, Computer programs in biomedicine.

[29]  N. Nie,et al.  Statistical Package for the Social Sciences , 1970 .